Could cause temporary or reversible harm; serious harm is unlikely.
Failed Tablet/Capsule Specifications: Capsule shell (s) opening inside the bottle The Initial reports stated one or two capsules in a bottle count of 30s opening. First report came in June 14, 2016. Till date about 22 reports have come in from pharmacies which report two batches 130/16/001 and 130/16/002. Third batch 130/16/003 is not distributed yet, will be recalled from warehouse.
| Distributed by / for | Cipia USA, Inc., Miami, FL 33156 |
| NDC | 69097-298-02 |
| Full product label | Duloxetine Delayed-release Capsules USP 30 mg 30-count bottles, Rx Only, Manufactured by: Inventia Healthcare Private Limited Additional Ambermath M.I.D.C., Ambermath (East) 421506, INDIA, Distributed by: Cipia USA, Inc., Miami, FL 33156, NDC 69097-298-02 |
| Recalling firm | Inventia Healthcare Private Limited |
| Distribution | United States |
| Quantity | 46,848 delayed-release capsules |
| Recall initiated | 2016-10-19 |
| Report date | 2016-12-28 |
| Recall completed | 2017-06-01 |
| Recall number | D-0224-2017 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Thane N/A India |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗